Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

By Hanif W.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 807-811

Informa Healthcare

Access to resources Recommend Favorite

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

By Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 785-789

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

By Hassanein Mohamed   Hanif Wasim   Malik Waqar   Kamal Ali   Geransar Parnia   Lister Nicola   Andrews Chris   Barnett Anthony  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1367-1374

Informa Healthcare

Access to resources Recommend Favorite

Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 603-607

John Wiley & Sons Inc

Access to resources Recommend Favorite